Document is current
Any future updates will be listed below
-
Authors
Valenstein, Max L. https://orcid.org/0000-0001-7616-0148
Lalgudi, Pranav V. https://orcid.org/0000-0003-1653-2338
Kedir, Jibril F. https://orcid.org/0000-0002-1565-9049
Condon, Kendall J.
Platzek, Anna
Freund, Daniel G.
Taylor, Martin S. https://orcid.org/0000-0003-1560-9276
Xu, Yunhan
Chivukula, Raghu R.
Sabatini, David M. https://orcid.org/0000-0002-1446-7256
- License Information
-
More Information
Article History
Received: 9 September 2022
Accepted: 21 August 2024
First Online: 8 January 2025
Competing interests
: D.M.S. is a shareholder of Navitor Pharmaceuticals, which is targeting for therapeutic benefit the amino-acid-sensing pathway upstream of mTORC1.
